Dysregulated blood sugar — spanning insulin resistance, prediabetes, and type 2 diabetes — involves impaired insulin secretion, blunted cellular glucose uptake, and chronic low-grade inflammation degrading beta-cell function. Peptide research targets incretin signaling, insulin sensitization, mitochondrial efficiency, and gut-mediated glucose regulation.
1. Semaglutide — GLP-1 Agonist / Glucose-Dependent Insulin Stimulation
Semaglutide is a GLP-1 receptor agonist that stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces hepatic glucose output. It directly lowers fasting and postprandial blood glucose while improving HbA1c — the gold standard measure of long-term glucose control.
Dosing Protocol: 0.25 mg SubQ once weekly (starting dose). Titrate by 0.25 mg every 4 weeks based on tolerance and response. Maximum research dose: 2.4 mg/week.
2. Tirzepatide — Dual GIP/GLP-1 Agonist
Tirzepatide activates both GLP-1 and GIP receptors, providing superior glucose lowering compared to GLP-1 agonists alone. GIP receptor activation enhances insulin secretion synergistically with GLP-1 signaling and adds direct effects on adipose tissue glucose uptake. Clinical trials show HbA1c reductions of 2–2.5% — among the strongest of any pharmacological approach.
Dosing Protocol: 2.5 mg SubQ once weekly, titrating by 2.5 mg every 4 weeks to a target of 5–15 mg/week based on response and tolerability.
3. BPC-157 — Beta-Cell Protection / Anti-Inflammatory
Chronic hyperglycemia drives inflammatory damage to pancreatic beta cells. BPC-157 reduces NF-κB driven islet inflammation, supports nitric oxide-mediated pancreatic blood flow, and has demonstrated protective effects on beta-cell survival in diabetic rodent models. It also addresses the gut permeability that contributes to immune-mediated beta-cell destruction.
Dosing Protocol: 250–500 mcg SubQ daily, or 500 mcg oral (arginate form) for combined systemic and gut-mediated benefits. Cycle: 8–12 weeks.
4. MOTS-C — Mitochondrial Insulin Sensitizer
MOTS-C is a mitochondria-derived peptide that activates AMPK and enhances cellular glucose uptake independent of insulin — essentially mimicking the insulin-sensitizing effects of exercise at the cellular level. It improves skeletal muscle glucose metabolism and has shown impressive anti-diabetic effects in multiple preclinical studies.
Dosing Protocol: 5–10 mg SubQ 3–5x per week. Best timed around physical activity. Cycle: 4–8 weeks. Emerging peptide — dosing protocols still being established in research.
Semaglutide and Tirzepatide directly correct the incretin deficiency driving glucose dysregulation. BPC-157 addresses the inflammatory damage to beta cells that progressive diabetes causes. MOTS-C provides an insulin-independent glucose disposal mechanism that works synergistically with GLP-1 agonism to normalize cellular metabolic function.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).